title: Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.
abstract: Bisphosphonates are a type of drugs known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and, thus, bone resorption. Bisphosphonates are, therefore, very widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw and this is their principal risk. A 75-year-old woman received dental treatment before starting intravenous BP therapy for a breast cancer. She started intravenous bisphosphonate treatment with monthly protocol and after two years the patient presented a wound compatible with osteonecrosis of the jaw.
authors.affiliation: Pharmacological Research in Dentistry Group, Faculty of Dentistry, University of Granada, Granada, Spain. ggomez@ugr.es.
authors.forename: G
authors.initials: G
authors.lastname: Gómez-Moreno
authors.forename: M C
authors.initials: MC
authors.lastname: Arribas-Fernández
authors.forename: M
authors.initials: M
authors.lastname: Fernández-Guerrero
authors.forename: A
authors.initials: A
authors.lastname: Boquete-Castro
authors.forename: A
authors.initials: A
authors.lastname: Aguilar-Salvatierra
authors.forename: J
authors.initials: J
authors.lastname: Guardia
authors.forename: D
authors.initials: D
authors.lastname: Botticelli
authors.forename: J L
authors.initials: JL
authors.lastname: Calvo-Guirado
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007262:Infusions, Intravenous; D009067:Mouthwashes / Q000627:therapeutic use; D011862:Radiography, Panoramic; D013997:Time Factors; D014081:Tooth Extraction; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D009067:Mouthwashes; D000077211:Zoledronic Acid